Sonoma Pharmaceuticals (SNOA) Expected to Release Earnings on Wednesday

Sonoma Pharmaceuticals (NASDAQ:SNOA) is anticipated to post its results before the market opens on Wednesday, July 15th. Analysts expect the company to post earnings of ($0.24) per share and revenue of $5.5650 million for the quarter.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last announced its quarterly earnings data on Tuesday, June 16th. The company reported ($0.33) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.09). Sonoma Pharmaceuticals had a negative return on equity of 43.95% and a negative net margin of 16.26%.The firm had revenue of $5.56 million during the quarter, compared to the consensus estimate of $5.57 million.

Sonoma Pharmaceuticals Price Performance

Shares of NASDAQ:SNOA opened at $1.23 on Wednesday. The business’s fifty day moving average price is $1.14 and its two-hundred day moving average price is $2.26. The stock has a market capitalization of $5.89 million, a price-to-earnings ratio of -0.65 and a beta of 1.27. Sonoma Pharmaceuticals has a fifty-two week low of $0.85 and a fifty-two week high of $6.92.

Institutional Investors Weigh In On Sonoma Pharmaceuticals

A hedge fund recently raised its position in Sonoma Pharmaceuticals stock. DRW Securities LLC grew its position in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) by 257.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 60,977 shares of the company’s stock after purchasing an additional 43,907 shares during the period. DRW Securities LLC owned approximately 3.59% of Sonoma Pharmaceuticals worth $222,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 1.95% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings lowered shares of Sonoma Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, April 29th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc is a specialty dermatology company focused on developing and commercializing topical prescription and over-the-counter products for inflammatory and infectious skin conditions. Publicly traded on Nasdaq under the symbol SNOA, the company concentrates its efforts on areas such as acne, rosacea, dermatitis and wound care, aiming to provide physicians and patients with innovative treatment options.

At the heart of Sonoma’s technology platform lies its proprietary Triphasic drug delivery system, which enables the timed release of active ingredients through three distinct gel phases.